Early Trial Results Offer Hope for Patients With CMT

Early phase 2a trial results for ignaseclant, a novel skeletal muscle chloride channel inhibitor, show promise in improving muscle strength and motor function in patients with Charcot-Marie-Tooth disease, with a good safety profile and benefits lasting beyond treatment.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.